Recent advances in the imaging of pheochromocytomas and paragangliomas

Pheochromocytoma and paraganglioma (PPGL) belong to the family of neural crest cell-derived neoplasms, and can be widely distributed throughout the body. Over the past few years, with respect to these tumors, precision medicine has offered the promise of improved patient care. Through tumor visualiz...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of endocrine oncology Vol. 4; no. 3; pp. 137 - 144
Main Authors Taïeb, David, Wolf, Katherine I, Pacak, Karel
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.08.2017
Subjects
Abdomen
Cancer
F)fluoro-L-3,4-dihydroxyphenylalanine
Family medical history
gallium radioisotopes
Genetic engineering
Localization
Medical imaging
Metastasis
MRI
Mutation
Neck
neuroendocrine
Neuroendocrine tumors
paragangliomas
positron emission tomography
precision medicine
radionuclide therapy
somatostatin
theranostics
Tumors
Online AccessGet full text

Cover

More Information
Summary:Pheochromocytoma and paraganglioma (PPGL) belong to the family of neural crest cell-derived neoplasms, and can be widely distributed throughout the body. Over the past few years, with respect to these tumors, precision medicine has offered the promise of improved patient care. Through tumor visualization and identification of molecular signatures, nuclear medicine is capable of playing a key role in PPGL precision medicine. Ga-labeled somatostatin analogs were found to improve the detection and staging of head and neck paragangliomas, -related PPGLs and metastatic PPGLs regardless of genetic background. For PPGLs associated with increased kinase signaling or mutations, F-fluorodihydroxyphenylalanine appears to be the most informative radiopharmaceutical. This review emphasizes the current theranostic approaches and future perspective related to PPGL imaging options.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:2045-0869
2045-0877
DOI:10.2217/ije-2017-0004